Yoshihiko Kakinuma1, Martin Fronius2, Rajesh Katare3, Eng Leng Saw4, James T Pearson5,6, Daryl O Schwenke4, Pujika Emani Munasinghe4, Hirotsugu Tsuchimochi5, Shruti Rawal4, Sean Coffey7, Philip Davis8, Richard Bunton8, Isabelle Van Hout4, Yuko Kai9, Michael J A Williams7. 1. Department of Bioregulatory Science, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. k12417853@nms.ac.jp. 2. Department of Physiology, HeartOtago, School of Biomedical Sciences, University of Otago, 270, Great King Street, Dunedin, 9016, New Zealand. martin.fronius@otago.ac.nz. 3. Department of Physiology, HeartOtago, School of Biomedical Sciences, University of Otago, 270, Great King Street, Dunedin, 9016, New Zealand. rajesh.katare@otago.ac.nz. 4. Department of Physiology, HeartOtago, School of Biomedical Sciences, University of Otago, 270, Great King Street, Dunedin, 9016, New Zealand. 5. Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan. 6. Biomedicine Discovery Institute and Department of Physiology, Monash University, Melbourne, VIC, Australia. 7. Department of Medicine, School of Medicine, University of Otago, Dunedin, New Zealand. 8. Department of Cardiothoracic Surgery, School of Medicine, University of Otago, Dunedin, New Zealand. 9. Department of Bioregulatory Science, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Abstract
BACKGROUND: Acetylcholine (ACh) plays a crucial role in the function of the heart. Recent evidence suggests that cardiomyocytes possess a non-neuronal cholinergic system (NNCS) that comprises of choline acetyltransferase (ChAT), choline transporter 1 (CHT1), vesicular acetylcholine transporter (VAChT), acetylcholinesterase (AChE) and type-2 muscarinic ACh receptors (M2AChR) to synthesize, release, degrade ACh as well as for ACh to transduce a signal. NNCS is linked to cardiac cell survival, angiogenesis and glucose metabolism. Impairment of these functions are hallmarks of diabetic heart disease (DHD). The role of the NNCS in DHD is unknown. The aim of this study was to examine the effect of diabetes on cardiac NNCS and determine if activation of cardiac NNCS is beneficial to the diabetic heart. METHODS: Ventricular samples from type-2 diabetic humans and db/db mice were used to measure the expression pattern of NNCS components (ChAT, CHT1, VAChT, AChE and M2AChR) and glucose transporter-4 (GLUT-4) by western blot analysis. To determine the function of the cardiac NNCS in the diabetic heart, a db/db mouse model with cardiac-specific overexpression of ChAT gene was generated (db/db-ChAT-tg). Animals were followed up serially and samples collected at different time points for molecular and histological analysis of cardiac NNCS components and prosurvival and proangiogenic signaling pathways. RESULTS: Immunoblot analysis revealed alterations in the components of cardiac NNCS and GLUT-4 in the type-2 diabetic human and db/db mouse hearts. Interestingly, the dysregulation of cardiac NNCS was followed by the downregulation of GLUT-4 in the db/db mouse heart. Db/db-ChAT-tg mice exhibited preserved cardiac and vascular function in comparison to db/db mice. The improved function was associated with increased cardiac ACh and glucose content, sustained angiogenesis and reduced fibrosis. These beneficial effects were associated with upregulation of the PI3K/Akt/HIF1α signaling pathway, and increased expression of its downstream targets-GLUT-4 and VEGF-A. CONCLUSION: We provide the first evidence for dysregulation of the cardiac NNCS in DHD. Increased cardiac ACh is beneficial and a potential new therapeutic strategy to prevent or delay the development of DHD.
BACKGROUND:Acetylcholine (ACh) plays a crucial role in the function of the heart. Recent evidence suggests that cardiomyocytes possess a non-neuronal cholinergic system (NNCS) that comprises of choline acetyltransferase (ChAT), choline transporter 1 (CHT1), vesicular acetylcholine transporter (VAChT), acetylcholinesterase (AChE) and type-2 muscarinic ACh receptors (M2AChR) to synthesize, release, degrade ACh as well as for ACh to transduce a signal. NNCS is linked to cardiac cell survival, angiogenesis and glucose metabolism. Impairment of these functions are hallmarks of diabetic heart disease (DHD). The role of the NNCS in DHD is unknown. The aim of this study was to examine the effect of diabetes on cardiac NNCS and determine if activation of cardiac NNCS is beneficial to the diabetic heart. METHODS: Ventricular samples from type-2 diabetichumans and db/db mice were used to measure the expression pattern of NNCS components (ChAT, CHT1, VAChT, AChE and M2AChR) and glucose transporter-4 (GLUT-4) by western blot analysis. To determine the function of the cardiac NNCS in the diabetic heart, a db/db mouse model with cardiac-specific overexpression of ChAT gene was generated (db/db-ChAT-tg). Animals were followed up serially and samples collected at different time points for molecular and histological analysis of cardiac NNCS components and prosurvival and proangiogenic signaling pathways. RESULTS: Immunoblot analysis revealed alterations in the components of cardiac NNCS and GLUT-4 in the type-2 diabetichuman and db/db mouse hearts. Interestingly, the dysregulation of cardiac NNCS was followed by the downregulation of GLUT-4 in the db/db mouse heart. Db/db-ChAT-tg mice exhibited preserved cardiac and vascular function in comparison to db/db mice. The improved function was associated with increased cardiac ACh and glucose content, sustained angiogenesis and reduced fibrosis. These beneficial effects were associated with upregulation of the PI3K/Akt/HIF1α signaling pathway, and increased expression of its downstream targets-GLUT-4 and VEGF-A. CONCLUSION: We provide the first evidence for dysregulation of the cardiac NNCS in DHD. Increased cardiac ACh is beneficial and a potential new therapeutic strategy to prevent or delay the development of DHD.
Authors: Shruti Rawal; Pujika Emani Munasinghe; Prashanth Thevkar Nagesh; Jason Kar Sheng Lew; Gregory T Jones; Michael J A Williams; Philip Davis; Dick Bunton; Ivor F Galvin; Patrick Manning; Regis R Lamberts; Rajesh Katare Journal: Clin Sci (Lond) Date: 2017-03-13 Impact factor: 6.124
Authors: Brian N Finck; John J Lehman; Teresa C Leone; Michael J Welch; Michael J Bennett; Attila Kovacs; Xianlin Han; Richard W Gross; Ray Kozak; Gary D Lopaschuk; Daniel P Kelly Journal: J Clin Invest Date: 2002-01 Impact factor: 14.808
Authors: N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh Journal: Lancet Date: 2010-06-26 Impact factor: 202.731
Authors: D R Gehlert; L Dreshfield; F Tinsley; M J Benvenga; S Gleason; R W Fuller; D T Wong; S K Hemrick-Luecke Journal: J Pharmacol Exp Ther Date: 1998-10 Impact factor: 4.030
Authors: Sébastien M Labbé; Thomas Grenier-Larouche; Christophe Noll; Serge Phoenix; Brigitte Guérin; Eric E Turcotte; André C Carpentier Journal: Diabetes Date: 2012-11 Impact factor: 9.461
Authors: María Valero-Muñoz; Eng Leng Saw; Ryan M Hekman; Benjamin C Blum; Zaynab Hourani; Henk Granzier; Andrew Emili; Flora Sam Journal: Front Cardiovasc Med Date: 2022-08-25